Breaking News, Financial News

Financial Report: Abbott 1Q11

Pharmaceutical sales were $3.8 billion in the quarter, up 12%. Humira sales were up 18% to $1.6 billion.

Abbott 1Q11

1Q Revenues:
$9.0 billion (+17%)

1Q Earnings:
$864.0 million (-14%)

Comments:
Pharmaceutical sales were $3.8 billion in the quarter, up 12%. Humira sales were up 18% to $1.6 billion. Trilipix/TriCor sales were $372 million, up 28%. Kaletra sales dropped 15% to $248 million. Niaspan sales were up 11% to $226 million. Synthroid sales were $145 million, up 18%. R&D expenses were up 27% to $930 million. Medical device sales were $1.2 billion (+11%). Earnings were impacted by restructuring and integration costs for the Solvay Pharmaceuticals acquistion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters